BLS Pharmaceuticals Rebrands As Its German Growth Story Builds

Fund managers track a rapidly scaling contract manufacturer of medical cannabis, MDMA and psilocybin products expanding into Europe

30 Jun 2026 · 6 min read

A name change marked a new chapter for BLS Pharmaceuticals, formerly Bioxyne, in June 2026. Cyan Investment Management reported the rapidly growing licensed pharmaceutical manufacturer of controlled medicines, including cannabis, psilocybin and MDMA products, rebranded from Bioxyne to BLS alongside a 1-for-10 share consolidation, with the stock rising 16 per cent for the month as its market capitalisation grew past $200 million and investor interest continued building around its expanding international footprint.

Positioned as the 'Foxconn' of medical cannabis manufacturing

Tamim Funds Management's detailed thesis from mid-2025 laid out why the business attracted attention well before the rebrand. The manager described Bioxyne as having secured a comprehensive Good Manufacturing Practice licence covering an unusually broad product range, including flower, oils, gummies, MDMA and psilocybin, and likened the company to Foxconn in the electronics industry: rather than building its own consumer brands, it operates as a contract manufacturer charging per-unit fees to medical cannabis companies, minimising the risks associated with direct patient sales while capturing the economics of manufacturing at scale. With fully automated production lines capable of processing up to 6,000 kilograms of product monthly, the manager said the company held around 10 to 15 per cent of the Australian flower packing market.

We like to think of the company as the 'Foxconn' to the industry... We think of BXN as a 'Picks and Shovels' play to the sector, akin to Foxconn in China being the manufacturer for Apple products.

— Tamim Funds Management, Monthly Report, July 2025

Explosive growth through FY26

That manufacturing model translated into rapid growth through FY26. DMX Asset Management reported the company delivered what it considered the standout ASX micro-cap result of the reporting season in February 2026, with half-year net profit after tax of $7.3 million, up 121 per cent, and an EBITDA guidance upgrade of around 50 per cent to between $16.5 million and $19 million. By April, third-quarter revenue had grown 137 per cent year on year to $21.3 million, a 24 per cent increase on the December quarter, putting the stock on a price-to-earnings multiple of around 8 times at the midpoint of guidance. Tamim Funds Management's May 2026 update said the company was growing revenue around 132 per cent year on year with FY26 revenue guidance at a midpoint of A$70 million and around 25 per cent EBITDA margins, while remaining cash flow positive with $8 million of net cash on the balance sheet.

BXN leverages a hard to replicate regulatory stack to supply clinics and pharmacies in Australia, Germany and the UK. Near term growth drivers include a $50M German contract and a UK GMP facility due for completion and licensing in December.

— Tamim Funds Management, Monthly Report, May 2026

An expanding international footprint

Much of the growth story now rests on markets outside Australia. Cyan Investment Management reported in May 2026 that the company secured a $50 million exclusive German supply agreement and expanded into Latin America with a Costa Rica supply agreement for medicinal cannabis flower, following a manufacturing deal with Aurora Cannabis and a boost from the US government's reclassification of marijuana products in April. DMX Asset Management noted European revenue from the UK and Germany reached $2.4 million for the March quarter, up 34 per cent on the prior quarter, describing Germany in particular as likely to represent a big part of the company's growth story over the following six to twelve months given its market share there was still only around 1 per cent.

What managers are watching next

With FY27 guidance expected in August and Tamim Funds Management projecting sales above $100 million and EBITDA around $25 million for that year, the key questions for managers are whether a planned UK GMP facility completes licensing in December as scheduled, whether the German contract scales as expected given the company's still-small market share there, and whether founder and largest shareholder Sam Watson's measured, contract-manufacturing-led growth strategy continues delivering the consistent upgrades that have defined the stock's re-rating since its FY25 breakthrough.